Investors are cheering Allergan and jeering AbbVie after the announcement of a major acquisition.
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
Canopy Growth is spending more on this than its next three biggest rivals combined.
And two things you shouldn't expect for the big Canadian cannabis producer.
The chances for at least a couple of these catalysts happening appear to be really good.
Which stock wins in a one-on-one matchup between two top Canadian cannabis producers?
These stocks were huge winners last week. But can their momentum continue?
Investors are voting with their pocketbooks on these popular pot stocks.
And how you can potentially profit from the trend.
Which stock is likely to be the bigger winner between a top Canadian cannabis producer and one of the largest multistate U.S. cannabis companies?
Great businesses plus great growth opportunities could add up to 100% or more returns for these stocks.
The maker of clear dental aligners faces big challenges, but it has big opportunities, too.
The short answer: in great shape.
The Rise of the "Pot-Bots" -- Can Investors Profit From Technology That's Disrupting How Cannabis Is Sold?
This technology is intriguing and could change how cannabis and CBD are bought and sold. But are there any great investing opportunities?
Canopy's quarterly results are finally in. Here are the highlights -- and the lowlights.
The good news? The cause of the drop should be a temporary issue.
Believe it or not, these cannabis stocks are profitable and pay really attractive dividends.
Which stock wins in a matchup between a top U.S. cannabis operator and a fast-growing Canadian cannabis producer?
A big deal with a medical cannabis company provided a spark for Intrexon.
The price of Rockwell Medical's latest stock offering wasn't right for investors.